Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study

被引:4
|
作者
O'Hara, Montana [1 ,2 ]
Janda, Monika [3 ]
McCarthy, Alexandra L. [4 ,5 ]
Nicklin, James [1 ]
Walker, Graeme [6 ]
Obermair, Andreas [1 ,2 ]
机构
[1] Royal Brisbane & Womens Hosp, Queensland Ctr Gynaecol Canc, Brisbane, Qld, Australia
[2] Univ Queensland, Ctr Clin Res, Brisbane, Qld, Australia
[3] Univ Queensland, Fac Med, Ctr Hlth Serv Res, Brisbane, Qld, Australia
[4] Univ Queensland, Sch Nursing Midwifery & Social Work, Brisbane, Qld, Australia
[5] Mater Res Inst, Brisbane, Qld, Australia
[6] Gold Coast Univ Hosp, Southport, Qld, Australia
来源
基金
英国医学研究理事会;
关键词
Endometrial cancer; Levonorgestrel intrauterine device; Progestin; progesterone; Decision-making; Patient experience; OBESITY; WOMEN; RISK; MANAGEMENT; PERCEPTIONS; PREVENTION; KNOWLEDGE; OUTCOMES; THERAPY;
D O I
10.1016/j.gore.2021.100914
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The aim of the study was to obtain an in-depth understanding of the experience of women who received non-surgical treatment for endometrial adenocarcinoma (EAC) or endometrial hyperplasia with atypia (EHA). Enhanced understanding of women's experiences of non-surgical treatment is essential to inform counselling of the growing number of patients in this field. Methods: Individual semi-structured interviews were conducted with 21 women who received conservative (nonsurgical hormonal) treatment for early stage EAC or EHA using the levonorgestrel intrauterine device (LNG-IUD) as part of the feMMe trial (NCT01686126). All interviews were audiotaped and transcribed verbatim prior to content analysis. Results: Of the 21 women interviewed, ten received conservative treatment for early stage EAC and 11 received conservative treatment for EHA. Five overarching themes were identified: i) extensive information and support needs (e.g. understanding of how the LNG-IUD treatment worked); ii) gratitude for treatment choice and nonsurgical options (e.g. avoidance of potential risks associated with surgery); iii) onco-fertility (e.g. desire to maintain reproductive potential); iv) patient experience of overweight and obesity related to EAC development (e.g. history of trauma and disordered eating, multiple unsuccessful weight loss attempts); and v) patient experience of treatment options and actual non-surgical treatment (e.g. desire for early referral to counselling services). Conclusions: This qualitative investigation enabled novel insights into the treatment preferences and decisionmaking process of women with newly diagnosed EHA and EAC when offered non-surgical treatment options. These insights facilitate the development of pragmatic guidance and decision support tools that could be tested in future clinical trials.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer
    Hirata, Toru
    Kondo, Eiji
    Magawa, Shoichi
    Kubo-Kaneda, Michiko
    Nii, Masafumi
    Yoshida, Kenta
    Maezawa, Tadashi
    Tabata, Tsutomu
    Ikeda, Tomoaki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2022, 48 (12) : 3219 - 3225
  • [2] Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device
    Haimovich, Sergio
    Checa, Miguel A.
    Mancebo, Gemma
    Fuste, Pere
    Carreras, Ramon
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2008, 15 (05): : 1002 - 1004
  • [3] Levonorgestrel-Releasing Intrauterine Device Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
    Manal M. El Behery
    Hend S. Saleh
    Moustafa A. Ibrahiem
    Ebtesam M. Kamal
    Gamal A. Kassem
    Mohamed El Sayed Mohamed
    Reproductive Sciences, 2015, 22 : 329 - 334
  • [4] Levonorgestrel-Releasing Intrauterine Device Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
    El Behery, Manal M.
    Saleh, Hend S.
    Ibrahiem, Moustafa A.
    Kamal, Ebtesam M.
    Kassem, Gamal A.
    Mohamed, Mohamed El Sayed
    REPRODUCTIVE SCIENCES, 2015, 22 (03) : 329 - 334
  • [5] Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study
    Giampaolino, Pierluigi
    Sardo, Attilio Di Spiezio
    Mollo, Antonio
    Raffone, Antonio
    Travaglino, Antonio
    Boccellino, Antonio
    Zizolfi, Brunella
    Insabato, Luigi
    Zullo, Fulvio
    De Placido, Giuseppe
    Bifulco, Giuseppe
    JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2019, 26 (04) : 648 - 656
  • [7] The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia
    Chen, Xiaojun
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (04)
  • [8] Comparison of the effectiveness of the levonorgestrel-intrauterine device and oral progestogens on regression of endometrial hyperplasia without atypia
    Shen, Ye
    Fang, Hua
    Zhang, Yi
    Du, Yan
    Cai, Rong
    Zhao, Min
    Chen, Qi
    HELIYON, 2022, 8 (12)
  • [9] Comparison of Mirena and Liletta levonorgestrel intrauterine device for the treatment of endometrial intraepithelial neoplasia and low risk early-stage endometrial cancer
    Chaudhari, Sonal
    Lai, Tiffany
    Zakhour, Mae
    Baltayan, Armine
    Tan, Hongying Tina
    Sim, Myung-Shin
    Cohen, Joshua
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S129 - S129
  • [10] Conservative Treatment With Medroxyprogesterone Acetate Plus Levonorgestrel Intrauterine System for Early-Stage Endometrial Cancer in Young Women Pilot Study
    Kim, Mi Kyung
    Yoon, Bo Sung
    Park, Hyun
    Seong, Seok Ju
    Chung, Hyun Hoon
    Kim, Jae Weon
    Kang, Soon Beom
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (04) : 673 - 677